search
Back to results

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Primary Purpose

Cholangiocarcinoma

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
HAIC combined with donafenib and sintilimab
Sponsored by
Zhongda Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cholangiocarcinoma focused on measuring Hepatic arterial infusion chemotherapy, Donafenib, Sintilimab, Intrahepatic cholangiocarcinoma

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Unresectable or metastatic histologically or cytologically confirmed ICC
  • No previous systemic treatment or local anti-tumor treatment other than surgery (biliary drainage is allowed), admission was allowed for more than 6 months after the end of adjuvant therapy
  • Child-Pugh score ≤7
  • Life expectancy ≥ 3 months
  • At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria
  • Eastern Cooperative Oncology Group(ECOG) performance status (PS) ≤ 1
  • The functional indicators of important organs meet the following requirements:

    • Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1.5*10^9 /L; platelet (PLT) ≥ 80 *10^9 /L; hemoglobin (HGB) ≥ 9.0 g/dL
    • Bilirubin ≤ 1.5 times upper limits of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 times ULN
    • Serum creatinine ≤ 1.5 times ULN, and creatinine clearance ≥ 60 ml/min (calculated by Cockcroft-Gault formula)
    • International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN
    • Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline of TSH is outside the normal range, patients with normal total T3 (or FT3) and free tetraiodothyronine (FT4) can also be enrolled
    • The myocardial enzyme profile was within the normal range
  • For women who are not breastfeeding or pregnant, use contraception during treatment or 4 months after the end of treatment
  • Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of the trial
  • Patients who have signed Informed Consent Form (ICF) and are able to perform follow-up visits and the required procedures

Exclusion Criteria:

  • Other malignancies diagnosed within 5 years before the first dose, excluding radically cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and/or radically cured carcinoma in situ.
  • Pathological diagnosis of hepatocellular carcinoma (HCC), mixed cholangiocarcinoma and HCC, and other malignant components of non-cholangiocarcinoma
  • Receipt of treatment in other clinical trials within 4 weeks before the first dose
  • Previous receipt of any antibody treatment involving anti-PD-1, anti-PD-L1/L2, or anti-CTLA4 or other immunotherapies
  • Previous receipt of targeted drug(s)
  • Previous receipt of palliative radiotherapy for biliary tract tumors, except for postoperative adjuvant radiotherapy
  • Previous receipt of Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first dose
  • An active autoimmune disease requiring systemic therapy (e.g., palliative drugs, glucocorticoids, or immunosuppressants) developed within 2 years prior to first administration
  • Have received systemic glucocorticoid therapy (excluding nasal spray, inhalation, or other topical glucocorticoid) or any other form of immunosuppressive therapy during the 4 weeks prior to the study
  • Obstructive jaundice (active treatment, such as biliary drainage or stent, can be included after liver function recovery)
  • Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation is known
  • Known allergic patients to sintilimab, the active ingredient of donafinib or excipients of the drug under study
  • Not fully recovered from toxicity and/or complications associated with any intervention prior to initiation of treatment (i.e., ≤ grade 1 or baseline, excluding fatigue or hair loss)
  • Human immunodeficiency virus (HIV), HIV 1/2 antibody positive
  • Untreated active hepatitis B (defined as HBsAg positive with hepatitis B virus DNA (HBV-DNA) copy number greater than the ULN in the laboratory department of the research center) [Note: Hepatitis B patients who meet the following criteria can also be enrolled: 1) HBV DNA <2.5*10^3 copies/ml (500 IU/ml) before the first dose, should receive anti-HBV treatment throughout the study period; patients with anti-hepatitis B core antigen(HBc) (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation needs to be closely monitored]
  • Active HCV-infected subjects (HCV antibody positive and HCV-RNA level above the detection limit)
  • Live attenuated vaccine was administered within 4 weeks prior to initial administration
  • Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year)
  • Presence of any serious or uncontrolled systemic disease, including but not limited to:

    • Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
    • Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification ≥ grade 2
    • Any arterial/venous thromboembolic events within 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient cerebral ischemic attack, pulmonary embolism, deep vein thrombosis, or any other history of serious thromboembolism
    • Receipt of major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks before the first dose or having unhealed wounds, ulcers, or fractures. Receipt of tissue biopsy or other minor surgeries within 7 days before the first dose, barring venipuncture and catheterization for intravenous infusion
    • Uncontrolled hypertension (systolic greater than 140 mmHg or diastolic greater than 90 mmHg) after optimal medical treatment, with the history of hypertensive crisis or hypertensive encephalopathy
    • Active tuberculosis
    • Active or poorly clinically controlled serious infections
    • Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction, gastrointestinal perforation, abdominal fistula within the past 6 months
    • Liver disease such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis
    • Poor control of diabetes (fasting blood glucose > 10 mmol/L)
    • Urine protein ≥ ++, and 24-hour urine protein quantification >1.0 g
    • With mental disorders and unable to cooperate with the treatment
  • Unsuitable for enrollment judged by the investigator

Sites / Locations

  • Zhongda Hospital, Southeast UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HAIC combined with donafenib and sintilimab

Arm Description

HAIC- GEMOX regimen, Day 1, every 3 weeks (Q3W). The maximum of 6 times. Sintilimab will be given on Day 1, 200 mg i.v. Q3W.The longest treatment time is 24 months. Donafenib was taken orally at 0.2 bid on an empty stomach, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment.

Outcomes

Primary Outcome Measures

Objective response rate (ORR)
According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for unresectable intrahepatic cholangiocarcinoma
Intrahepatic objective response rate (hORR)
According to RECIST 1.1 for unresectable intrahepatic cholangiocarcinoma

Secondary Outcome Measures

Disease control rate (DCR)
The time from initiation of either regimen of combination therapy to all-cause death.
Duration of response (DOR)
max 24 months
Progression-free survival (PFS)
Time from initiation therapy to tumor progression according to the modified RECIST criteria or death from any cause.
Overall survival (OS)
The time from initiation of either regimen of combination therapy to all-cause death.
Adverse events
Adverse event (AE)、treatment emergent adverse event (TEAE)、serious adverse event (SAE).

Full Information

First Posted
April 20, 2022
Last Updated
December 28, 2022
Sponsor
Zhongda Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05348811
Brief Title
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Official Title
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Donafenib and Sintilimab in First-line Treatment of Unresectable Intrahepatic Cholangiocarcinoma (ICC): a Prospective, Open-label, Phase II Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 28, 2022 (Actual)
Primary Completion Date
June 15, 2023 (Anticipated)
Study Completion Date
July 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhongda Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
Detailed Description
Compared with systemic intravenous chemotherapy, hepatic arterial infusion chemotherapy(HAIC) has the advantages of improving local drug concentration and reducing toxic and side effects. Currently, it is gradually used in the treatment of intrahepatic cholangiocarcinoma (ICC) with good safety and high objective response rate. Immunotherapy combined with targeted and chemotherapy was well tolerated. At present, anti-programmed cell death protein-1(PD-1) antibody combined with chemotherapy and targeted therapy for advanced biliary tract tumors has initially shown good safety and encouraging efficacy, which is worthy of further exploration. Therefore, this study aims to evaluate the efficacy and safety of HAIC (GEMOX regimen) combined with donafenib and sintilimab in unresectable ICC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholangiocarcinoma
Keywords
Hepatic arterial infusion chemotherapy, Donafenib, Sintilimab, Intrahepatic cholangiocarcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
HAIC (GEMOX regimen) combined with donafenib and sintilimab
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HAIC combined with donafenib and sintilimab
Arm Type
Experimental
Arm Description
HAIC- GEMOX regimen, Day 1, every 3 weeks (Q3W). The maximum of 6 times. Sintilimab will be given on Day 1, 200 mg i.v. Q3W.The longest treatment time is 24 months. Donafenib was taken orally at 0.2 bid on an empty stomach, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment.
Intervention Type
Drug
Intervention Name(s)
HAIC combined with donafenib and sintilimab
Other Intervention Name(s)
HAIC-donafenib-sintilimab
Intervention Description
HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter > 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times. Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months. Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or > 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol.
Primary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for unresectable intrahepatic cholangiocarcinoma
Time Frame
max 24 months
Title
Intrahepatic objective response rate (hORR)
Description
According to RECIST 1.1 for unresectable intrahepatic cholangiocarcinoma
Time Frame
max 24 months
Secondary Outcome Measure Information:
Title
Disease control rate (DCR)
Description
The time from initiation of either regimen of combination therapy to all-cause death.
Time Frame
max 24 months
Title
Duration of response (DOR)
Description
max 24 months
Time Frame
max 24 months
Title
Progression-free survival (PFS)
Description
Time from initiation therapy to tumor progression according to the modified RECIST criteria or death from any cause.
Time Frame
max 24 months
Title
Overall survival (OS)
Description
The time from initiation of either regimen of combination therapy to all-cause death.
Time Frame
max 42 months
Title
Adverse events
Description
Adverse event (AE)、treatment emergent adverse event (TEAE)、serious adverse event (SAE).
Time Frame
max 42 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Unresectable or metastatic histologically or cytologically confirmed ICC No previous systemic treatment or local anti-tumor treatment other than surgery (biliary drainage is allowed), admission was allowed for more than 6 months after the end of adjuvant therapy Child-Pugh score ≤7 Life expectancy ≥ 3 months At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria Eastern Cooperative Oncology Group(ECOG) performance status (PS) ≤ 1 The functional indicators of important organs meet the following requirements: Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1.5*10^9 /L; platelet (PLT) ≥ 80 *10^9 /L; hemoglobin (HGB) ≥ 9.0 g/dL Bilirubin ≤ 1.5 times upper limits of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 times ULN Serum creatinine ≤ 1.5 times ULN, and creatinine clearance ≥ 60 ml/min (calculated by Cockcroft-Gault formula) International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline of TSH is outside the normal range, patients with normal total T3 (or FT3) and free tetraiodothyronine (FT4) can also be enrolled The myocardial enzyme profile was within the normal range For women who are not breastfeeding or pregnant, use contraception during treatment or 4 months after the end of treatment Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of the trial Patients who have signed Informed Consent Form (ICF) and are able to perform follow-up visits and the required procedures Exclusion Criteria: Other malignancies diagnosed within 5 years before the first dose, excluding radically cured basal cell carcinoma of skin, squamous cell carcinoma of skin, and/or radically cured carcinoma in situ. Pathological diagnosis of hepatocellular carcinoma (HCC), mixed cholangiocarcinoma and HCC, and other malignant components of non-cholangiocarcinoma Receipt of treatment in other clinical trials within 4 weeks before the first dose Previous receipt of any antibody treatment involving anti-PD-1, anti-PD-L1/L2, or anti-CTLA4 or other immunotherapies Previous receipt of targeted drug(s) Previous receipt of palliative radiotherapy for biliary tract tumors, except for postoperative adjuvant radiotherapy Previous receipt of Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first dose An active autoimmune disease requiring systemic therapy (e.g., palliative drugs, glucocorticoids, or immunosuppressants) developed within 2 years prior to first administration Have received systemic glucocorticoid therapy (excluding nasal spray, inhalation, or other topical glucocorticoid) or any other form of immunosuppressive therapy during the 4 weeks prior to the study Obstructive jaundice (active treatment, such as biliary drainage or stent, can be included after liver function recovery) Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation is known Known allergic patients to sintilimab, the active ingredient of donafinib or excipients of the drug under study Not fully recovered from toxicity and/or complications associated with any intervention prior to initiation of treatment (i.e., ≤ grade 1 or baseline, excluding fatigue or hair loss) Human immunodeficiency virus (HIV), HIV 1/2 antibody positive Untreated active hepatitis B (defined as HBsAg positive with hepatitis B virus DNA (HBV-DNA) copy number greater than the ULN in the laboratory department of the research center) [Note: Hepatitis B patients who meet the following criteria can also be enrolled: 1) HBV DNA <2.5*10^3 copies/ml (500 IU/ml) before the first dose, should receive anti-HBV treatment throughout the study period; patients with anti-hepatitis B core antigen(HBc) (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but viral reactivation needs to be closely monitored] Active HCV-infected subjects (HCV antibody positive and HCV-RNA level above the detection limit) Live attenuated vaccine was administered within 4 weeks prior to initial administration Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year) Presence of any serious or uncontrolled systemic disease, including but not limited to: Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification ≥ grade 2 Any arterial/venous thromboembolic events within 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient cerebral ischemic attack, pulmonary embolism, deep vein thrombosis, or any other history of serious thromboembolism Receipt of major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks before the first dose or having unhealed wounds, ulcers, or fractures. Receipt of tissue biopsy or other minor surgeries within 7 days before the first dose, barring venipuncture and catheterization for intravenous infusion Uncontrolled hypertension (systolic greater than 140 mmHg or diastolic greater than 90 mmHg) after optimal medical treatment, with the history of hypertensive crisis or hypertensive encephalopathy Active tuberculosis Active or poorly clinically controlled serious infections Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction, gastrointestinal perforation, abdominal fistula within the past 6 months Liver disease such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis Poor control of diabetes (fasting blood glucose > 10 mmol/L) Urine protein ≥ ++, and 24-hour urine protein quantification >1.0 g With mental disorders and unable to cooperate with the treatment Unsuitable for enrollment judged by the investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hai-Dong Zhu
Phone
86-25-83262224
Email
zhuhaidong9509@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hui-Yan Dong
Phone
86-25-83262224
Email
ljxxdhy@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gao-Jun Teng
Organizational Affiliation
Zhongda Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Zhongda Hospital, Southeast University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hai-Dong Zhu
Phone
86-25-83262224
Email
zhuhaidong9509@163.com

12. IPD Sharing Statement

Learn more about this trial

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

We'll reach out to this number within 24 hrs